Ocugen Inc. closed 73.92% short of its 52-week high of $2.11, which the company reached on March 25th.

After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will continue.

US-based biotechnology company Ocugen has received approval from the Data and Safety Monitoring Board (DSMB) to begin dosing ...

Ocugen Inc. closed 75.47% below its 52-week high of $2.11, which the company reached on March 25th.

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

Ocugen (OCGN) stock was up today after the biotech company posted results from its Q4 2024 earnings report. Earnings per share reported during ...

Ocugen (OCGN) announced that the Data and Safety Monitoring Board for the OCU200 clinical trial recently convened and reviewed safety data ...

March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that ...

Ocugen reported clinical trial progress and financial results, highlighting advancements in gene therapies for retinal diseases and recent FDA alignments. OCU410ST is a therapy for Stargardt ...

March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that ...

Ocugen ( NASDAQ:OCGN ) Full Year 2024 Results Key Financial Results Net loss: US$54.1m (loss narrowed by 14% from FY... MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the ...

Ocugen ( NASDAQ:OCGN ) Full Year 2024 Results Key Financial Results Net loss: US$54.1m (loss narrowed by 14% from FY... MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the ...